Corcept CBO exercises options for 17,493 shares
Corcept Therapeutics Inc. (CORT) reports that Chief Business Officer Gary Charles Robb exercised options for 17,493 shares of common stock on September 17, 2026 at an exercise price of $8.27 per share, converting a fully exercisable option into common shares.
Rhea-AI Filing Summary
Corcept Therapeutics Inc. (CORT) reports that Chief Business Officer Gary Charles Robb exercised options for 17,493 shares of common stock on September 17, 2026 at an exercise price of $8.27 per share, converting a fully exercisable option into common shares. Following this transaction, he holds 31,156 common shares directly, including 1,663 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their grant dates if conditions are met, and continues to hold 182,507 options directly that expire on February 10, 2027. He also has indirect ownership of 39,716 common shares through a revocable trust for which he is trustee, plus additional indirect holdings in custodial accounts for his children, and no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
17,493 shares exercised/converted
Exercise
5 txns
Insider
Robb Gary Charles
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) F5 | 17,493 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 17,493 | $8.27 | $145K |
| holding | Common Stock F2 | -- | -- | -- |
| holding | Common Stock F3 | -- | -- | -- |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 182,507 contracts (Direct);
Common Stock — 31,156 shares (Direct);
Common Stock — 39,716 shares (Indirect, Gary Charles Robb TTE Robb Revocable Trust);
Common Stock — 31,142 shares (Indirect, Custodial Account for Child)
Footnotes (5)
- F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- F2. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
- F3. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
- F4. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
- F5. Fully exercisable.
Key Figures
Options exercised: 17,493 shares
Exercise price: $8.27 per share
Direct common shares after transaction: 31,156 shares
+3 more
6 metrics
Options exercised
17,493 shares
Options exercised into common stock on September 17, 2026
Exercise price
$8.27 per share
Price paid to exercise 17,493 options on September 17, 2026
Direct common shares after transaction
31,156 shares
Direct holdings of common stock after September 17, 2026 transaction
Unvested restricted stock awards included in direct holdings
1,663 shares
Unvested restricted stock awards granted on December 1, 2025, March 2, 2026, June 1, 2026 and September 1, 2026
Remaining options
182,507 options
Directly held options after exercise, expiring February 10, 2027
Indirect trust holdings
39,716 shares
Common shares held in a revocable trust for which the reporting person is trustee
Key Terms
restricted stock awards, revocable trust, Uniform Transfers to Minors Act, Rule 10b5-1 trading plan
4 terms
restricted stock awards financial
"shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
revocable trust financial
"held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Uniform Transfers to Minors Act financial
"custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian"
Rule 10b5-1 trading plan regulatory
"no Rule 10b5-1 trading plan is reported for this transaction"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corcept Therapeutics (CORT) report about Gary Charles Robb’s latest Form 4 transaction?
Corcept Therapeutics reported that Chief Business Officer Gary Charles Robb exercised options for 17,493 shares of common stock on September 17, 2026 at an exercise price of $8.27 per share, converting a fully exercisable option into common shares.
What stock options in Corcept Therapeutics (CORT) remain for Gary Charles Robb after the exercise?
Following the September 17, 2026 exercise, Gary Charles Robb continues to hold 182,507 stock options in Corcept Therapeutics directly, with an exercise price of $8.27 per share and an expiration date of February 10, 2027.
What indirect holdings of Corcept Therapeutics (CORT) stock does Gary Charles Robb report?
Gary Charles Robb reports indirect ownership of 39,716 Corcept Therapeutics common shares through a revocable trust for which he is trustee, as well as additional indirect holdings in custodial accounts for his children under the Uniform Transfers to Minors Act.
Were Gary Charles Robb’s Corcept Therapeutics (CORT) transactions under a Rule 10b5-1 plan?
No. The filing indicates that no Rule 10b5-1 trading plan is reported for Gary Charles Robb’s September 17, 2026 option exercise and related share acquisition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
